Open AccessChimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in psoriasis
Author(s) -
Jayashree Sridhar,
PLK Desylva,
YD Singh
Publication year - 2006
Publication title -
indian journal of dermatology venereology and leprology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.514
H-Index - 45
eISSN - 0973-3922
pISSN - 0378-6323
DOI - 10.4103/0378-6323.25639
Subject(s) - infliximab , psoriasis , medicine , tumor necrosis factor alpha , monoclonal antibody , pathogenesis , adverse effect , gastroenterology , immunology , monoclonal , antibody
Insights into the pathogenesis of psoriasis have provided opportunities to target key steps in the disease process. Tumor necrosis factor-alpha (TNF- alpha) being crucial to the pathogenesis of psoriasis, monoclonal antibodies against this cytokine have proved useful in its treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom